We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Eye Care

Journal Scan / Research · August 12, 2020

Faricimab vs Ranibizumab for the Treatment of nAMD

JAMA ophthalmology


Additional Info

JAMA ophthalmology
Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The AVENUE Phase 2 Randomized Clinical Trial
JAMA Ophthalmol 2020 Jul 30;[EPub Ahead of Print], J Sahni, PU Dugel, SS Patel, ME Chittum, B Berger, M Del Valle Rubido, S Sadikhov, P Szczesny, D Schwab, E Nogoceke, R Weikert, S Fauser

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading